


Research in Your Backyard

Developing Cures, Creating Jobs



**PHARMACEUTICAL
CLINICAL TRIALS IN
ILLINOIS**

Dots show locations of clinical trials in the state.

PhARMA

Executive Summary

This report shows that biopharmaceutical research companies continue to be vitally important to the economy and patient health in Illinois, despite the recession.

At a time when the state still faces significant economic challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical trials of new medicines in collaboration with the state's clinical research centers, university medical schools and hospitals. Of the more than 4,300 clinical trials, 2,334 target or have targeted the nation's six most debilitating chronic diseases—**asthma, cancer, diabetes, heart disease, mental illnesses and stroke.**

What are Clinical Trials?

In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration to approve treatments. Clinical tests of new drugs are conducted in three phases and account for seven of the 10 to 15 years required for drug development and approval.

Clinical trials involve thousands of volunteer patient participants, the generation of tens of thousands of pages of technical and scientific data and are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine.

Quite often, biopharmaceutical companies hire local research institutions to conduct the tests and in Illinois, they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, Quincy, Rock Island, Rockford and Springfield.

For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them. More than 470 of the trials underway in Illinois are still recruiting patients.

Participants in clinical trials can:

- Play an active role in their health care.
- Gain access to new research treatments before they are widely available.
- Obtain expert medical care at leading health care facilities during the trial.
- Help others by contributing to medical research.

Patient Safety in Clinical Trials

- All tests must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.

- Clinical trial progress reports must be submitted at least annually to the Food and Drug Administration and the IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Many different entities and individuals contribute to the safe and appropriate conduct of clinical research, including not only sponsoring companies but also regulatory agencies; investigative site staff and medical professionals who serve as clinical investigators; hospitals and other institutions where research is conducted; and institutional review boards and ethics committees.

Local Involvement

Illinois institutions involved in clinical tests of treatments include medical schools, research centers and hospitals, such as:

- Rush University Medical Center in Chicago
- Cedar-Crosse Research Center in Chicago
- Loyola University Medical Center in Maywood
- Decatur Memorial Hospital Cancer Institute in Skokie

- North Shore University Medical Center in Skokie
- Northwestern University Feinberg School of Medicine in Chicago
- Rush University in Chicago
- Southern Illinois University Medical Center in Springfield
- The University of Chicago Medical Center in Chicago

The biopharmaceutical research companies working with these institutions have targeted disease wisely—more than half of Illinois’s new medicine clinical trials are aimed at chronic conditions that plague patients all over the state, including cancer, diabetes, heart disease and stroke.

There are 474 clinical trials recruiting patients all over the state. These trials target the top six chronic diseases—**asthma, cancer, diabetes, heart disease, mental illness and stroke.**

Equally as important is the fact that many of the medicines being clinically tested here are new-generation biotechnology treatments. With biotechnology, we have the potential to develop safer and more effective therapies and we can improve our ability to predict, preempt or even prevent disease.

Economic Impact of Biopharmaceutical Companies

Earlier reports show biopharmaceutical research companies have been an important source of jobs, tax revenue and research spending:

- A study by Archstone Consulting found that in 2008 the industry supported more than 167,000 jobs throughout the state.

Clinical Trials in Illinois since 1999— Completed and Active	
All Clinical Trials	Six Major Chronic Diseases
4,395	2,334

Source: www.clinicaltrials.gov
 Note: Search criteria = Illinois, Phase I, II, III; industry only.
 Search performed 2/1/2012.

“At a time when the state is focused on creating jobs and rebuilding the economy, clinical research and the biopharmaceutical industry have been real bright spots. These companies provide thousands of good-paying jobs, and to the extent they succeed in finding innovative medicines, they make the entire workforce stronger and more productive.”

—David Miller, President and CEO
iBIO (Illinois Biotechnology Industry Organization)

- The employees working directly for the companies were paid \$2.8 billion, leading to more than \$75 million in state taxes and more than \$710 million in federal taxation.
- Biopharmaceutical research firms that year also invested \$2.3 billion in research and development and provided \$43.9 billion in products and services.
- Company employees in Illinois include life sciences researchers, management executives, office and administrative support workers, engineers, architects, computer and math experts and sales representatives.

Clinical Trials in Illinois Communities

Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Chicago	4	28	35	22	30	11
Decatur	0	18	0	0	0	0
Joliet	0	15	1	3	10	0
Peoria	0	19	4	4	2	2
Quincy	0	11	2	2	0	2
Rock Island	0	1	0	2	0	1
Rockford	0	4	0	2	0	1
Springfield	1	12	10	4	4	3

Source: www.clinicaltrials.gov

Note: Search criteria = Illinois, Phase I, II, III; industry only. Search performed 2/1/2012. See Appendix for detailed information about these clinical trials. Disease columns will not add to totals in Appendix because some clinical trials are recruiting in more than one city.

“As part of our mission to improve quality of life for people living with lung disease, Respiratory Health Association of Metropolitan Chicago devotes significant resources each year to funding research. Through support of investigators at local institutions including Northwestern University, University of Chicago and University of Illinois at Chicago, we hope to develop interventions, improve treatments and discover cures for lung diseases.”

—Joel Africk, President and Chief Executive Officer
Respiratory Health Association of Metropolitan Chicago

Many of these medicines are being tested today in clinical trials throughout Illinois.

At a time when tens of thousands of state residents are suffering from one or more chronic diseases, America’s biopharmaceutical research companies are sponsoring or have sponsored 2,334 clinical trials of potential new medicines in the Prairie State alone for asthma, cancer, heart disease, stroke, diabetes and mental illnesses. Of the 2,334 trials, 474 are either not yet recruiting or are just now seeking Illinois patients, giving those still searching for effective treatments potential new options and new hope.

Many of the state’s clinical tests involve collaborations with such respected local institutions as the Loyola University’s Medical Center in Maywood, the North Shore University Health System in Evanston, the University of Chicago and the University of Illinois in Chicago.

The Need for New Chronic Disease Medicines

Chronic diseases pose the greatest threats to our nation’s health and our ability to treat and prevent medical conditions. According to the Centers for Disease Control and Prevention, today, in the United States:

- Patients with chronic diseases account for 75 cents of every dollar spent on health care.
- Chronic diseases are the leading cause of death and disability.
- Chronic diseases are a leading driver of rising health care costs with expenses totaling billions of dollars every year.

With the stakes so high, America’s biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	74	11
Cancer	1,294	303
Diabetes	293	41
Heart Disease	210	30
Mental Illness	422	78
Stroke	41	11
Total	2,334	474

Source: www.clinicaltrials.gov

Note: Search criteria = Illinois, Phase I, II, III; industry only. Search performed 2/1/2012.

Clinical Trials in Illinois

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the \$1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The Food and Drug Administration (FDA) is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	74	11
Cancer	1,294	303
Diabetes	293	41
Heart Disease	210	30
Mental Illness	422	78
Stroke	41	11
Total	2,334	474

Source: www.clinicaltrials.gov

Note: Search criteria = Illinois, Phase I, II, III; industry only. Search performed 2/1/2012.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Illinois, biopharmaceutical companies have the luxury of having trials conducted at the states' well-respected university medical schools, comprehensive cancer centers and clinical trial research centers. According to *U.S. News and World Report*, University of Chicago's Pritzker School of Medicine ranked 12th, Northwestern University's Feinberg School of Medicine ranked 19th, the University of Illinois College of Medicine ranked 56th, Rush University College of Medicine ranked 70th

and the **Stritch School of Medicine at Loyola University** ranked 71st among this year's top 100 research-oriented medical schools in the United States.

Asthma is a debilitating condition for more than 24 million Americans, including 7 million children under the age of 18. The toll is also severe in Illinois—in 2007, about 12.8 percent of adults had asthma and 14 percent of children suffered from asthma, according to the Illinois Department of Public Health.

Currently, 11 clinical trials of new asthma medicines are recruiting patients in Illinois. In Chicago, trials are being conducted at **Rush University Medical Center** and **Cedar-Crosse Research Center**. **Loyola University Medical Center** in Maywood is also conducting clinical tests.

Cancer, the second leading cause of death in the United States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Illinois, more than 65,000 new cancer cases will be diagnosed this year and 23,970 victims in the state will die, according to the American Cancer Society.

Currently, 303 clinical trials of new cancer medicines are recruiting patients in Illinois. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **Cardinal Bernardin Cancer Center at Loyola University** in Maywood, the **Robert H. Lurie Cancer Center at Northwestern University** in Chicago, the **Decatur Memorial Hospital Cancer Care Institute** and the **North Shore University Medical Center** in Skokie.

Diabetes affects more than 25 million Americans—about 8 percent of the U.S. population—and nearly one-third are unaware they have the disease. In Illinois, about 500,000 adults have been diagnosed with diabetes, according to the Illinois Department of Public Health.

Currently, 41 diabetes clinical tests are seeking patients in Illinois. In Chicago, the trials are being conducted at

Northwestern University Feinberg School of Medicine, **Rush University** and the **University of Illinois**. Other institutions include **Edward Hines Jr. VA Hospital** in Hines and **Ingalls Memorial Hospital** in Harvey.

Heart Disease and Stroke are the first and fourth leading disease causes of death in the United States and the first and third in Illinois. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Illinois, in 2008, nearly 26,000 residents died from some form of heart disease and nearly 6,000 died from a stroke, according to the Illinois Department of Public Health.

Currently, 30 heart disease and 11 stroke clinical tests are seeking patients in Illinois. The trials are being conducted at the **Midwest Heart Foundation** in Lombard, the **Rehabilitation Institute of Chicago at Northwestern University** in Chicago, and the **Southern Illinois University Medical Center** in Springfield.

Mental Illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Illinois, more than 700,000 adults live with serious mental illness and about 240,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 78 clinical trials are recruiting patients in Illinois. The trials are taking place at the **University of Chicago Medical Center** and the **Department of Psychiatry & Behavioral Sciences at Northwestern University** in Chicago, and the **Alexian Brothers Behavioral Health Hospital** in Hoffman Estates.

Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored by the National Institutes of Health. Information on medicines in development is also available on www.phrma.org, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA).

New Generation Medicines in Development

Many of the medicines being tested in Illinois are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Illinois is one of the states where new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict, preempt and prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is

being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at Illinois medical schools and research centers feature these technologies. For example:

- A genetically-modified virus-based vaccine to treat melanoma.
- An antisense medicine for the treatment of cancer.
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat age-related macular degeneration and diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation's biopharmaceutical companies and Illinois research institutions are working together to attack disease. The biotechnology medicines and vaccines in development promise to push the frontiers of science and potentially bring more and better treatments to patients.

Conclusion

Biopharmaceutical companies' close collaboration with clinicians and research institutions in Illinois benefits patients, the state's economy and the advancement of science and patient care. Clinical trial business is good business for the state's medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Illinoisans contemplating participation in clinical trials have a wide range of choices—more than 470 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they need patient volunteers

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials						
	Discovery/ Preclinical Testing	Phase I	Phase II	Phase III	FDA	Phase IV
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug

Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I. These tests usually involve about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

Clinical Trials, Phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

Clinical Trials, Phase III. This phase usually involves 1,000 to 5,000 patients in clinics and

hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 21 new therapeutics approved by the FDA in 2010 was 14.8 months.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. Pharmaceutical companies invested an estimated \$67.4 billion in research and development in 2010.

The Good News – Many Clinical Trials are Still Recruiting

There are 474 clinical trials recruiting in Illinois. These trials target the top six chronic diseases and other debilitating diseases affecting Americans and Illinoisans.

Clinical Trials in Illinois Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Chicago	4	218	35	22	30	11
Decatur	0	18	0	0	0	0
Joliet	0	15	1	3	10	0
Peoria	0	19	4	4	2	2
Quincy	0	11	2	2	0	2
Rock Island	0	1	0	2	0	1
Rockford	0	4	0	2	0	1
Springfield	1	12	10	4	4	3

Source: www.clinicaltrials.gov

Note: Search criteria = Illinois, Phase I, II, III; industry only. Search performed 2/1/2012. See Appendix for detailed information about these clinical trials. Disease columns will not add to totals in Appendix because some clinical trials are recruiting in more than one city.

Asthma—Leading Institutions Conducting Clinical Trials

Cedar-Crosse Research Center, Chicago
Loyola University Medical Center, Maywood
Northern Illinois Research Associates, DeKalb
Rush University Medical Center, Chicago

Cancer—Leading Institutions Conducting Clinical Trials

Adventist Hinsdale Hospital, Hinsdale
Advocate Christ Medical Center, Oak Lawn
Advocate Lutheran General Cancer Care Center, Park Ridge
Advocate Lutheran General Hospital, Niles
Cancer Research Center, University of Chicago Hospitals,
Chicago

The Good News—Many Clinical Trials are Still Recruiting

Cancer—Leading Institutions

Conducting Clinical Trials (continued)

Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood
Carle Cancer Center, Urbana
Carle Foundation Hospital, Urbana
CCOP North Shore University Health System, Evanston
Central DuPage Hospital Cancer Center, Warrendale
Central DuPage Hospital, Winfield
Children’s Memorial Hospital at Northwestern University, Chicago
Clintell, Skokie
Comers Children’s Hospital at the University of Chicago, Chicago
Creticos Cancer Center, Chicago
Crossroads Cancer Center, Effingham
Decatur Memorial Hospital Cancer Care Institute, Decatur
Delnor Community Hospital, Geneva
Edward Cancer Center, Naperville
Edward Hines Jr. VA Hospital, Hines
Elmhurst Memorial Hospital, Elmhurst
Feinberg School of Medicine at Northwestern University, Chicago
Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital, Downers Grove
Ingalls Cancer Research Center, Harvey
John H. Stroger Jr. Hospital of Cook County, Chicago
Kellogg Cancer Care Center, Evanston
Loyola University Chicago, Maywood
Midwestern Regional Medical Center, Zion
North Central Cancer Treatment Group, Illinois Cancer Care, Peoria
North Chicago VA Hospital, North Chicago
North Shore Cancer Research Association, Skokie
North Shore University Medical Center, Evanston
Northwest Community Hospital, Arlington Heights
Northwestern Medical Faculty Foundation at Northwestern University, Chicago
Orchard Healthcare Research, Skokie
Robert H. Lurie Cancer Center at Northwestern University, Chicago
Rush University Medical Center, Chicago
Southern Illinois University Hematology/Oncology, Centralia
Southern Illinois University School of Medicine, Springfield
Swedish-American Regional Cancer Center, Rockford
The Cancer Institute at Alexian Brothers, Elk Grove Village
The University of Illinois at Chicago, Chicago
University of Chicago Cancer Research Center, Chicago
University of Chicago Medical Center, Chicago
University of Illinois Cancer Center, Chicago
UroPartners/RMD Clinical Research, Melrose Park
Warren Billhartz Cancer Center at Anderson Hospital, Maryville

Diabetes—Leading Institutions

Conducting Clinical Trials

Cedar-Crosse Research Center, Chicago
American Medical Research, Oak Brook
AMR Sakeena Research, Aurora
Apex Clinical Research, Chicago
Cedar Crosse Research Center, Chicago
Chicago Clinical Research Institute, Chicago
Chicago Research Center, Chicago
Edward Hines Jr. VA Hospital, Hines
Feinberg School of Medicine at Northwestern University, Chicago
ICCT Research International, Chicago
Ingalls Memorial Hospital, Harvey
John H. Stroger Jr. Hospital of Cook County, Chicago
Loyola University Medical Center, Maywood
OSF St. Francis Medical Center, Peoria
Rush University, Chicago
Southern Illinois Clinical Research Center, O’Fallon
University of Illinois, Chicago

Heart Disease and Stroke—Leading Institutions

Conducting Clinical Trials

Advocate Medical, Park Ridge
Evanston Northwestern Healthcare at Evanston Hospital, Evanston
Ingalls Memorial Hospital, Harvey
John H. Stroger Jr. Hospital of Cook County, Chicago
Loyola University Medical Center, Maywood
Midwest Heart Foundation, Lombard
North Shore University, Evanston
Northwestern University, Chicago
OSF St. Francis Medical Center, Peoria
Prairie Education Research Cooperative, Springfield
Rehabilitation Institute of Chicago at Northwestern University, Chicago
Rush University Medical Center, Chicago
Southern Illinois University Neurology, Springfield
St. John’s Hospital and Memorial Medical Center at Prairie Heart Cooperative, Springfield
University of Chicago, Chicago
University of Illinois, Chicago

Mental Illness—Leading Institutions

Conducting Clinical Trials

Alexian Brothers Behavioral Health Hospital, Hoffman Estates
American Medical Research, Oak Brook
AMR-Baber Research, Naperville
Capstone Clinical Research, Libertyville
Chicago Research Center, Chicago
Feinberg School of Medicine at Northwestern University, Chicago
Institute for Juvenile Research, Chicago
Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace
Northwestern University, Chicago
Rush University Medical Center, Chicago
Thresholds Psychiatric Rehabilitation Center, Chicago
University of Chicago Medical Center, Chicago

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov*, the clinical tests database of the National Institutes of Health.

Asthma

(11 clinical trials recruiting)

Study 1:

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

<http://ClinicalTrials.gov/show/NCT00809757>

Study 2:

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

<http://ClinicalTrials.gov/show/NCT00941798>

Study 3:

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma I

<http://ClinicalTrials.gov/show/NCT01172808>

Study 4:

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

<http://ClinicalTrials.gov/show/NCT01285323>

Study 5:

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

<http://ClinicalTrials.gov/show/NCT00838591>

Study 6:

A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma

<http://ClinicalTrials.gov/show/NCT01402986>

Study 7:

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

<http://ClinicalTrials.gov/show/NCT00642616>

Study 8:

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day (BAI)

<http://ClinicalTrials.gov/show/NCT01360021>

Study 9:

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067 AM1)

<http://ClinicalTrials.gov/show/NCT01385371>

Study 10:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

<http://ClinicalTrials.gov/show/NCT01008410>

Study 11:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

<http://ClinicalTrials.gov/show/NCT01008423>

Cancer

(303 clinical trials recruiting)

Study 1:

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01217697>

Study 2:

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01355302>

Study 3:

Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

<http://ClinicalTrials.gov/show/NCT01132664>

Study 4:

A Study of Onartuzumab (MetMab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

<http://ClinicalTrials.gov/show/NCT01456325>

Study 5:

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01355484>

Study 6:

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

<http://ClinicalTrials.gov/show/NCT01358877>

Study 7:

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

<http://ClinicalTrials.gov/show/NCT01355497>

Study 8:

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy

<http://ClinicalTrials.gov/show/NCT01419197>

Study 9:

The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01506609>

Study 10:

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01374425>

Study 11:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

<http://ClinicalTrials.gov/show/NCT01351415>

Study 12:

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01297419>

Study 13:

A Study of Onartuzumab (MetMab) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01519804>

Study 14:

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

<http://ClinicalTrials.gov/show/NCT01437566>

Study 15:

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

<http://ClinicalTrials.gov/show/NCT01478594>

Study 16:

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

<http://ClinicalTrials.gov/show/NCT01077154>

Study 17:

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

<http://ClinicalTrials.gov/show/NCT01221077>

Study 18:

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

<http://ClinicalTrials.gov/show/NCT01204749>

Study 19:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

<http://ClinicalTrials.gov/show/NCT00858364>

Study 20:

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

<http://ClinicalTrials.gov/show/NCT00911170>

Study 21:

Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT00721409>

Study 22:

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01007942>

Study 23:

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

<http://ClinicalTrials.gov/show/NCT00968968>

Study 24:

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01234337>

Study 25:

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT00724503>

Study 26:

A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

<http://ClinicalTrials.gov/show/NCT01120184>

Study 27:

Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

<http://ClinicalTrials.gov/show/NCT00320710>

Study 28:

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01373164>

Study 29:

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00531284>

Study 30:

Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
<http://ClinicalTrials.gov/show/NCT00849667>

Study 31:

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
<http://ClinicalTrials.gov/show/NCT01137968>

Study 32:

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
<http://ClinicalTrials.gov/show/NCT01309126>

Study 33:

A Study in Second Line Metastatic Colorectal Cancer
<http://ClinicalTrials.gov/show/NCT01183780>

Study 34:

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Cancer
<http://ClinicalTrials.gov/show/NCT00643318>

Study 35:

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
<http://ClinicalTrials.gov/show/NCT01173497>

Study 36:

Immunotherapy Study for Surgically Resected Pancreatic Cancer
<http://ClinicalTrials.gov/show/NCT01072981>

Study 37:

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
<http://ClinicalTrials.gov/show/NCT01256762>

Study 38:

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
<http://ClinicalTrials.gov/show/NCT01031225>

Study 39:

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
<http://ClinicalTrials.gov/show/NCT01272791>

Study 40:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
<http://ClinicalTrials.gov/show/NCT01170650>

Study 41:

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
<http://ClinicalTrials.gov/show/NCT01348126>

Study 42:

Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
<http://ClinicalTrials.gov/show/NCT01337089>

Study 43:

Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
<http://ClinicalTrials.gov/show/NCT01234402>

Study 44:

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With Castrate Resistant Prostate Cancer (CRPC)
<http://ClinicalTrials.gov/show/NCT01083615>

Study 45:

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
<http://ClinicalTrials.gov/show/NCT01057810>

Study 46:

Study of Immunotherapy to Treat Advanced Prostate Cancer
<http://ClinicalTrials.gov/show/NCT00861614>

Study 47:

A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00762034>

Study 48:

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01326000>

Study 49:

GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

<http://ClinicalTrials.gov/show/NCT01231347>

Study 50:

A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

<http://ClinicalTrials.gov/show/NCT00883116>

Study 51:

Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00686959>

Study 52:

Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

<http://ClinicalTrials.gov/show/NCT01285609>

Study 53:

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

<http://ClinicalTrials.gov/show/NCT01225172>

Study 54:

ARCHER 1009 : A Phase 3 Study Of PF-00299804, A Pan-HER Inhibitor, Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01360554>

Study 55:

Study of Patients With Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00948675>

Study 56:

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT00856375>

Study 57:

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01075048>

Study 58:

A Study in Second Line Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01168973>

Study 59:

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01268059>

Study 60:

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

<http://ClinicalTrials.gov/show/NCT01154140>

Study 61:

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01212991>

Study 62:

Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT00864110>

Study 63:

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

<http://ClinicalTrials.gov/show/NCT00649207>

Study 64:

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases (GRABM-B)

<http://ClinicalTrials.gov/show/NCT01480583>

Study 65:

Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01454102>

Study 66:

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

<http://ClinicalTrials.gov/show/NCT01497665>

Study 67:

EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01360840>

Study 68:

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

<http://ClinicalTrials.gov/show/NCT01395017>

Study 69:

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01483586>

Study 70:

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

<http://ClinicalTrials.gov/show/NCT01308567>

Study 71:

Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01395758>

Study 72:

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

<http://ClinicalTrials.gov/show/NCT01387269>

Study 73:

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01471197>

Study 74:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01479465>

Study 75:

NP2 Enkephalin For Treatment of Intractable Cancer Pain

<http://ClinicalTrials.gov/show/NCT01291901>

Study 76:

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)

<http://ClinicalTrials.gov/show/NCT01399684>

Study 77:

A Study of Onartuzumab (MetMab) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01496742>

Study 78:

A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01160744>

Study 79:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

<http://ClinicalTrials.gov/show/NCT00045968>

Study 80:

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT00854152>

Study 81:

A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

<http://ClinicalTrials.gov/show/NCT01316263>

Study 82:

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01472198>

Study 83:

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ (ADXS11-001)

<http://ClinicalTrials.gov/show/NCT01116245>

Study 84:

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

<http://ClinicalTrials.gov/show/NCT00878436>

Study 85:

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01160211>

Study 86:

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

<http://ClinicalTrials.gov/show/NCT01450761>

Study 87:

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01186861>

Study 88:

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

<http://ClinicalTrials.gov/show/NCT01331941>

Study 89:

Umbilical Cord Transplantation for the Elderly Population

<http://ClinicalTrials.gov/show/NCT01484470>

Study 90:

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

<http://ClinicalTrials.gov/show/NCT01465659>

Study 91:

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (RESUME)

<http://ClinicalTrials.gov/show/NCT01178281>

Study 92:

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

<http://ClinicalTrials.gov/show/NCT01455493>

Study 93:

Efficacy and Safety of Masitinib in Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01470131>

Study 94:

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01432353>

Study 95:

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

<http://ClinicalTrials.gov/show/NCT01393964>

Study 96:

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

<http://ClinicalTrials.gov/show/NCT01441973>

Study 97:

A Study of Siltuximab (Anti-IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01484275>

Study 98:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

<http://ClinicalTrials.gov/show/NCT01480479>

Study 99:

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

<http://ClinicalTrials.gov/show/NCT01498328>

Study 100:

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

<http://ClinicalTrials.gov/show/NCT01453205>

Study 101:

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01335009>

Study 102:

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

<http://ClinicalTrials.gov/show/NCT01220271>

Study 103:

Philips Pivotal Clinical Trial for MRI-HIFU of Uterine Fibroids

<http://ClinicalTrials.gov/show/NCT01504308>

Study 104:

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

<http://ClinicalTrials.gov/show/NCT01227551>

Study 105:

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01435369>

Study 106:

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01327885>

Study 107:

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma (BOLT)

<http://ClinicalTrials.gov/show/NCT01327053>

Study 108:

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01034631>

Study 109:

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

<http://ClinicalTrials.gov/show/NCT01295710>

Study 110:

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

<http://ClinicalTrials.gov/show/NCT01423539>

Study 111:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01460160>

Study 112:

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

<http://ClinicalTrials.gov/show/NCT01466179>

Study 113:

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

<http://ClinicalTrials.gov/show/NCT01330966>

Study 114:

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

<http://ClinicalTrials.gov/show/NCT00827138>

Study 115:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Post-remission Chemotherapy for Leukemia

<http://ClinicalTrials.gov/show/NCT01297543>

Study 116:

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

<http://ClinicalTrials.gov/show/NCT01433731>

Study 117:

A Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01261312>

Study 118:

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

<http://ClinicalTrials.gov/show/NCT01475955>

Study 119:

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Locations: Galesburg

<http://ClinicalTrials.gov/show/NCT00981058>

Study 120:

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung

Locations: Chicago

<http://ClinicalTrials.gov/show/NCT01082549>

Study 121:

ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01244191>

Study 122:

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01211483>

Study123:

A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

<http://ClinicalTrials.gov/show/NCT01246960>

Study 124:

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01200992>

Study 125:

A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01288911>

Study 126:

A Study in Head and Neck Cancer

<http://ClinicalTrials.gov/show/NCT01081041>

Study 127:

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Patients With Gastric Cancer and Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT00917384>

Study 128:

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

<http://ClinicalTrials.gov/show/NCT00424255>

Study 129:

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Postmenopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

<http://ClinicalTrials.gov/show/NCT00696072>

Study 130:

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

<http://ClinicalTrials.gov/show/NCT00820222>

Study 131:

A Trial In Patients With Advanced Cancer And Leukemia

<http://ClinicalTrials.gov/show/NCT00878189>

Study 132:

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

<http://ClinicalTrials.gov/show/NCT01194960>

Study 133:

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01415960>

Study 134:

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01361607>

Study 135:

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

<http://ClinicalTrials.gov/show/NCT01314118>

Study 136:

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00840749>

Study 137:

A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT00918203>

Study 138:

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

<http://ClinicalTrials.gov/show/NCT01234038>

Study 139:

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

<http://ClinicalTrials.gov/show/NCT01313663>

Study 140:

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

<http://ClinicalTrials.gov/show/NCT01381874>

Study 141:

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01234311>

Study 142:

Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT00733850>

Study 143:

A Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01321554>

Study 144:

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01283373>

Study 145:

TNferade Biologic to Treat Locally Advanced Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01048151>

Study 146:

A Study of Dulanermin Administered in Combination With Camptosar®/Erbix® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
<http://ClinicalTrials.gov/show/NCT00671372>

Study 147:

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
<http://ClinicalTrials.gov/show/NCT00885963>

Study 148:

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
<http://ClinicalTrials.gov/show/NCT00874107>

Study 149:

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
<http://ClinicalTrials.gov/show/NCT01038752>

Study 150:

A Study of RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
<http://ClinicalTrials.gov/show/NCT01286753>

Study 151:

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
<http://ClinicalTrials.gov/show/NCT00660101>

Study 152:

A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
<http://ClinicalTrials.gov/show/NCT00585195>

Study 153:

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
<http://ClinicalTrials.gov/show/NCT00652626>

Study 154:

Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
<http://ClinicalTrials.gov/show/NCT01284348>

Study 155:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
<http://ClinicalTrials.gov/show/NCT00891137>

Study 156:

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
<http://ClinicalTrials.gov/show/NCT00940316>

Study 157:

A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas
<http://ClinicalTrials.gov/show/NCT00844649>

Study 158:

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
<http://ClinicalTrials.gov/show/NCT00803647>

Study 159:

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
<http://ClinicalTrials.gov/show/NCT01087970>

Study 160:

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
<http://ClinicalTrials.gov/show/NCT00654836>

Study 161:

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
<http://ClinicalTrials.gov/show/NCT00919035>

Study 162:

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

<http://ClinicalTrials.gov/show/NCT01087697>

Study 163:

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

<http://ClinicalTrials.gov/show/NCT01300858>

Study 164:

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00613626>

Study 165:

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

<http://ClinicalTrials.gov/show/NCT00566618>

Study 166:

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01363024>

Study 167:

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

<http://ClinicalTrials.gov/show/NCT01060514>

Study 168:

A Dose-escalation Study in Subjects With Advanced Malignancies

<http://ClinicalTrials.gov/show/NCT01195311>

Study 169:

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

<http://ClinicalTrials.gov/show/NCT01372579>

Study 170:

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

<http://ClinicalTrials.gov/show/NCT01125566>

Study 171:

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT00924352>

Study 172:

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

<http://ClinicalTrials.gov/show/NCT01433263>

Study 173:

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

<http://ClinicalTrials.gov/show/NCT01294202>

Study 174:

Study Evaluating Toxicity & Efficacy of Lenalidomide (Revlimid®) in Chemotherapy-Naïve AIPC Patients

<http://ClinicalTrials.gov/show/NCT00654186>

Study 175:

Phase 2 Study of Efficacy and Safety of Apricoxib/ Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients

<http://ClinicalTrials.gov/show/NCT00771953>

Study 176:

Study of Ruxolitinib in Pancreatic Cancer Patients

<http://ClinicalTrials.gov/show/NCT01423604>

Study 177:

Tolerability Study of Xerecept® in Pediatric Patients

<http://ClinicalTrials.gov/show/NCT01369121>

Study 178:

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

<http://ClinicalTrials.gov/show/NCT01247246>

Study 179:

Stage IIIB/IV Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01179269>

Study 180:

Laser Based Focal Ablation of Low Grade Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01192438>

Study 181:

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01259089>

Study 182:

Study of PM01183 in Non-Colorectal Cancer Patients as Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

<http://ClinicalTrials.gov/show/NCT01405391>

Study 183:

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01110486>

Study 184:

A Study of the Specificity and Sensitivity of 5-Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors

<http://ClinicalTrials.gov/show/NCT01128218>

Study 185:

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01063816>

Study 186:

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01383538>

Study 187:

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT00726037>

Study 188:

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

<http://ClinicalTrials.gov/show/NCT01140607>

Study 189:

Study of Breast Cancer Prevention by Letrozole in High Risk Women

<http://ClinicalTrials.gov/show/NCT00579826>

Study 190:

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

<http://ClinicalTrials.gov/show/NCT00920140>

Study 191:

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

<http://ClinicalTrials.gov/show/NCT01158300>

Study 192:

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01095120>

Study 193:

Trial of Poor Performance Status Patients (ToPPS)

<http://ClinicalTrials.gov/show/NCT00892710>

Study 194:

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

<http://ClinicalTrials.gov/show/NCT00275067>

Study 195:

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

<http://ClinicalTrials.gov/show/NCT01235962>

Study 196:

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

<http://ClinicalTrials.gov/show/NCT01149668>

Study 197:

A Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

<http://ClinicalTrials.gov/show/NCT01204164>

Study 198:

A Study in Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01232452>

Study 199:

Dose Escalation Study of RAD001 in Combination w/ Chemotherapy & Radiation in Patients With NSCLC

<http://ClinicalTrials.gov/show/NCT01063478>

Study 200:

Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

<http://ClinicalTrials.gov/show/NCT01133678>

Study 201:

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01219010>

Study 202:

A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver

<http://ClinicalTrials.gov/show/NCT00906373>

Study 203:

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01262651>

Study 204:

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

<http://ClinicalTrials.gov/show/NCT01384292>

Study 205:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01321346>

Study 206:

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

<http://ClinicalTrials.gov/show/NCT01166542>

Study 207:

IMA901 in Patients Receiving Sunitinib for Advanced/ Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01265901>

Study 208:

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01063907>

Study 209:

Treatment of Blood Clots in Children With Cancer

<http://ClinicalTrials.gov/show/NCT00952380>

Study 210:

Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01029873>

Study 211:

Cetuximab and Lenalidomide in Head and Neck

<http://ClinicalTrials.gov/show/NCT01133665>

Study 212:

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

<http://ClinicalTrials.gov/show/NCT00998192>

Study 213:

A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

<http://ClinicalTrials.gov/show/NCT01218516>

Study 214:

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01023308>

Study 215:

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

<http://ClinicalTrials.gov/show/NCT01002248>

Study 216:

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01335399>

Study 217:

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01001442>

Study 218:

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01353222>

Study 219:

An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

<http://ClinicalTrials.gov/show/NCT00947856>

Study 220:

An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

<http://ClinicalTrials.gov/show/NCT00555906>

Study 221:

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

<http://ClinicalTrials.gov/show/NCT01023880>

Study 222:

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

<http://ClinicalTrials.gov/show/NCT01121120>

Study 223:

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

<http://ClinicalTrials.gov/show/NCT00916409>

Study 224:

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

<http://ClinicalTrials.gov/show/NCT00815607>

Study 225:

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01191801>

Study 226:

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00963820>

Study 227:

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00461045>

Study 228:

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01215136>

Study 229:

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01108445>

Study 230:

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

<http://ClinicalTrials.gov/show/NCT01127451>

Study 231:

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

<http://ClinicalTrials.gov/show/NCT01208662>

Study 232:

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

<http://ClinicalTrials.gov/show/NCT01158885>

Study 233:

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01380106>

Study 234:

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

<http://ClinicalTrials.gov/show/NCT01351935>

Study 235:

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01014208>

Study 236:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced L-sarcoma

<http://ClinicalTrials.gov/show/NCT01343277>

Study 237:

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

<http://ClinicalTrials.gov/show/NCT01028222>

Study 238:

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

<http://ClinicalTrials.gov/show/NCT01140347>

Study 239:

Phase I Biomarker Study (BMS-936558)

<http://ClinicalTrials.gov/show/NCT01358721>

Study 240:

Study of MDX-1203 in Subjects With Advanced/ Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

<http://ClinicalTrials.gov/show/NCT00944905>

Study 241:

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

<http://ClinicalTrials.gov/show/NCT01124539>

Study 242:

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

<http://ClinicalTrials.gov/show/NCT01280552>

Study 243:

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

<http://ClinicalTrials.gov/show/NCT01268566>

Study 244:

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

<http://ClinicalTrials.gov/show/NCT01032070>

Study 245:

A Study of LY2157299 in Patients With Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01246986>

Study 246:

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01271803>

Study 247:

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

<http://ClinicalTrials.gov/show/NCT01397708>

Study 248:

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01168791>

Study 249:

A Study Evaluating the Efficacy and Safety of GDC-0449 in Operable Basal Cell Carcinoma (BCC)
<http://ClinicalTrials.gov/show/NCT01201915>

Study 250:

A Study to Provide Access to Trabectedin in Patients With Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
<http://ClinicalTrials.gov/show/NCT00210665>

Study 251:

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
<http://ClinicalTrials.gov/show/NCT01141491>

Study 252:

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
<http://ClinicalTrials.gov/show/NCT00859222>

Study 253:

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
<http://ClinicalTrials.gov/show/NCT00724984>

Study 254:

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
<http://ClinicalTrials.gov/show/NCT01087151>

Study 255:

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma
<http://ClinicalTrials.gov/show/NCT01059630>

Study 256:

Vaccination Plus Ontak in Patients With Metastatic Melanoma
<http://ClinicalTrials.gov/show/NCT00515528>

Study 257:

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
<http://ClinicalTrials.gov/show/NCT00788775>

Study 258:

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
<http://ClinicalTrials.gov/show/NCT01242488>

Study 259:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
<http://ClinicalTrials.gov/show/NCT01321541>

Study 260:

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
<http://ClinicalTrials.gov/show/NCT00774345>

Study 261:

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
<http://ClinicalTrials.gov/show/NCT01241500>

Study 262:

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
<http://ClinicalTrials.gov/show/NCT00590187>

Study 263:

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
<http://ClinicalTrials.gov/show/NCT01200589>

Study 264:

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
<http://ClinicalTrials.gov/show/NCT00948090>

Study 265:

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT00963105>

Study 266:

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The “EMERGE” Trial

<http://ClinicalTrials.gov/show/NCT00737529>

Study 267:

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

<http://ClinicalTrials.gov/show/NCT00790036>

Study 268:

Study of Elacytarabine Versus Investigator’s Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

<http://ClinicalTrials.gov/show/NCT01147939>

Study 269:

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01287741>

Study 270:

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin’s Lymphoma Who Have Received Prior Treatment

Locations: Chicago, Maywood

<http://ClinicalTrials.gov/show/NCT01007292>

Study 271:

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01188681>

Study 272:

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01349049>

Study 273:

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01197560>

Study 274:

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

<http://ClinicalTrials.gov/show/NCT00866281>

Study 275:

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

<http://ClinicalTrials.gov/show/NCT01100502>

Study 276:

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01390337>

Study 277:

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

<http://ClinicalTrials.gov/show/NCT01232556>

Study 278:

CLL11: A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01010061>

Study 279:

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01363297>

Study 280:

A Study in Patients With Acute Leukemia

<http://ClinicalTrials.gov/show/NCT01214603>

Study 281:

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL

<http://ClinicalTrials.gov/show/NCT00520208>

Study 282:

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

<http://ClinicalTrials.gov/show/NCT00910910>

Study 283:

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

<http://ClinicalTrials.gov/show/NCT00931918>

Study 284:

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

<http://ClinicalTrials.gov/show/NCT00980018>

Study 285:

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01217229>

Study 286:

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

<http://ClinicalTrials.gov/show/NCT00777036>

Study 287:

A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01300247>

Study 288:

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01414855>

Study 289:

A Study of RO5072759 (GA101) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT01332968>

Study 290:

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT01303796>

Study 291:

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01265199>

Study 292:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

<http://ClinicalTrials.gov/show/NCT00981799>

Study 293:

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

<http://ClinicalTrials.gov/show/NCT01029730>

Study 294:

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01361711>

Study 295:

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT00703820>

Study 296:

EZN-3042 Administered With Re-induction
Chemotherapy in Children With Relapsed Acute
Lymphoblastic Leukemia (ALL)

<http://ClinicalTrials.gov/show/NCT01186328>

Study 297:

Phase II R-ABVD Versus ABVD for Advanced Stage
Classical Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT00654732>

Study 298:

Temsirolimus for Relapsed/Refractory Hodgkin's
Lymphoma

<http://ClinicalTrials.gov/show/NCT00838955>

Study 299:

A Phase I Study of AC220 for Children With Relapsed
or Refractory Acute Lymphoblastic Leukemia or Acute
Myelogenous Leukemia

<http://ClinicalTrials.gov/show/NCT01411267>

Study 300:

Rituximab, Ifosfamide, Carboplatin, and Etoposide
(RICE) Followed by Gallium Nitrate, Rituximab and
Dexamethasone (GARD) for Relapsed or Refractory
Diffuse Large B-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT00836173>

Study 301:

Myelodysplastic Syndromes (MDS) Event Free Survival
With Iron Chelation Therapy Study

<http://ClinicalTrials.gov/show/NCT00940602>

Study 302:

A Study of Lenalidomide Versus Placebo in Subjects
With Transfusion Dependent Anemia in Low Risk
Myelodysplastic Syndrome (MDS) Without Del 5Q

<http://ClinicalTrials.gov/show/NCT01029262>

Study 303:

A Trial of Lenalidomide & Azacitidine in Low Risk
Myelodysplastic Syndromes

<http://ClinicalTrials.gov/show/NCT01379274>

Diabetes

(41 clinical trials recruiting)

Study 1:

A Study in Patients With Type 2 Diabetes Mellitus
(IMAGINE 2)

<http://ClinicalTrials.gov/show/NCT01435616>

Study 2:

A Trial Comparing the Efficacy and Safety of Insulin
Degludec/Liraglutide and Insulin Degludec in Subjects
With Type 2 Diabetes (DUAL™ II)

<http://ClinicalTrials.gov/show/NCT01392573>

Study 3:

Study to Evaluate the Efficacy, Safety, Tolerability, and
Pharmacokinetics of Saxagliptin as Monotherapy in
Pediatric Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01204775>

Study 4:

CAROLINA: Cardiovascular Outcome Study of
Linagliptin Versus Glimepiride in Patients With Type 2
Diabetes

<http://ClinicalTrials.gov/show/NCT01243424>

Study 5:

A Study of BMS-512148 (Dapagliflozin) in Patients
With Type 2 Diabetes With Inadequately Controlled
Hypertension on an ACEI or ARB and an Additional
Antihypertensive Medication

<http://ClinicalTrials.gov/show/NCT01195662>

Study 6:

A Study of BMS-512148 (Dapagliflozin) in Patients
With Type 2 Diabetes With Inadequately Controlled
Hypertension on an Angiotensin-Converting Enzyme
Inhibitor (ACEI) or Angiotensin Receptor Blocker
(ARB)

<http://ClinicalTrials.gov/show/NCT01137474>

Study 7:

12 Week Efficacy and Safety Study of BI 10773 in
Hypertensive Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01370005>

Study 8:

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

<http://ClinicalTrials.gov/show/NCT01131676>

Study 9:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01144338>

Study 10:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT00968708>

Study 11:

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01351675>

Study 12:

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01042769>

Study 13:

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01276106>

Study 14:

Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT00789750>

Study 15:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

<http://ClinicalTrials.gov/show/NCT01499082>

Study 16:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

<http://ClinicalTrials.gov/show/NCT01499095>

Study 17:

A Study in Adults With Type 1 Diabetes (ELEMENT 1)

<http://ClinicalTrials.gov/show/NCT01421147>

Study 18:

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT00658021>

Study 19:

A Study in Patients With Type I Diabetes Mellitus (IMAGINE 3)

<http://ClinicalTrials.gov/show/NCT01454284>

Study 20:

A Study in Participants With Type 2 Diabetes Mellitus (IMAGINE 4)

<http://ClinicalTrials.gov/show/NCT01468987>

Study 21:

Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01289990>

Study 22:

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01306214>

Study 23:

Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

<http://ClinicalTrials.gov/show/NCT01422876>

Study 24:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

<http://ClinicalTrials.gov/show/NCT01434186>

Study 25:

Study of Safety and Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01336738>

Study 26:

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01472185>

Study 27:

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01494987>

Study 28:

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation

<http://ClinicalTrials.gov/show/NCT01179048>

Study 29:

Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01456195>

Study 30:

Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01451398>

Study 31:

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

<http://ClinicalTrials.gov/show/NCT01206101>

Study 32:

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
<http://ClinicalTrials.gov/show/NCT01414920>

Study 33:

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
<http://ClinicalTrials.gov/show/NCT00642616>

Study 34:

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
<http://ClinicalTrials.gov/show/NCT01069965>

Study 35:

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
<http://ClinicalTrials.gov/show/NCT01183013>

Study 36:

Study of RO6807952 in Patients With Diabetes Mellitus Type 2
<http://ClinicalTrials.gov/show/NCT01516476>

Study 37:

Insulin Resistance Intervention After Stroke Trial
<http://ClinicalTrials.gov/show/NCT00091949>

Study 38:

A Study in Patients With Diabetic Kidney Disease
<http://ClinicalTrials.gov/show/NCT01113801>

Study 39:

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
<http://ClinicalTrials.gov/show/NCT01356849>

Study 40:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 41:

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

<http://ClinicalTrials.gov/show/NCT01399580>

Heart Disease (31 clinical trials recruiting)

Study 1:

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

<http://ClinicalTrials.gov/show/NCT01516541>

Study 2:

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

<http://ClinicalTrials.gov/show/NCT01234870>

Study 3:

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

<http://ClinicalTrials.gov/show/NCT01245634>

Study 4:

VIVID—Valvular and Ventricular Improvement Via iCoapsys Delivery—Feasibility Study

<http://ClinicalTrials.gov/show/NCT00512005>

Study 5:

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/ Emergency Department Visits or Cardiovascular Death in Patients With Implantable Cardioverter Defibrillators (ICDs) (SHIELD-2)

<http://ClinicalTrials.gov/show/NCT01464476>

Study 6:

A Study With Alogliptin in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01042769>

Study 7:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

<http://ClinicalTrials.gov/show/NCT01225562>

Study 8:

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

<http://ClinicalTrials.gov/show/NCT00683696>

Study 9:

The Evaluation of VAD InterVENTion Before Inotropic Therapy

<http://ClinicalTrials.gov/show/NCT01369407>

Study 10:

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

<http://ClinicalTrials.gov/show/NCT00990327>

Study 11:

RED-HF™ Tria—Reduction of Events With Darbeoetin Alfa in Heart Failure Trial

<http://ClinicalTrials.gov/show/NCT00358215>

Study 12:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT00968708>

Study 13:

Gene Therapy for the Treatment of Chronic Stable Angina

<http://ClinicalTrials.gov/show/NCT01002495>

Study 14:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 15:

AngelMed for Early Recognition and Treatment of STEMI

<http://ClinicalTrials.gov/show/NCT00781118>

Study 16:

Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy

<http://ClinicalTrials.gov/show/NCT01121107>

Study 17:

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT01130246>

Study 18:

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatid in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

<http://ClinicalTrials.gov/show/NCT01076764>

Study 19:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

<http://ClinicalTrials.gov/show/NCT01314313>

Study 20:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 21:

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) (RIVER-PCI)

<http://ClinicalTrials.gov/show/NCT01442038>

Study 22:

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

<http://ClinicalTrials.gov/show/NCT00520806>

Study 23:

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

<http://ClinicalTrials.gov/show/NCT01300013>

Study 24:

INcrease Of VAgal TonE in CHF (INOVATE-HF)

<http://ClinicalTrials.gov/show/NCT01303718>

Study 25:

Pivotal Study of a Percutaneous Mitral Valve Repair System (EVEREST II)

<http://ClinicalTrials.gov/show/NCT00209274>

Study 26:

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

<http://ClinicalTrials.gov/show/NCT01327183>

Study 27:

Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

<http://ClinicalTrials.gov/show/NCT01182441>

Study 28:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 29:

Ranolazine and Pulmonary Hypertension

<http://ClinicalTrials.gov/show/NCT01174173>

Study 30:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 31:

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01219010>

Mental Illness

(78 clinical trials recruiting)

Study 1:

Electronic Decision Support Systems for Smokers With Severe Mental Illness

<http://ClinicalTrials.gov/show/NCT01412866>

Study 2:

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

<http://ClinicalTrials.gov/show/NCT01360632>

Study 3:

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

<http://ClinicalTrials.gov/show/NCT01360866>

Study 4:

Efficacy in Prevention of Relapse of Schizophrenia in Subjects Taking Either Placebo or Iloperidone

<http://ClinicalTrials.gov/show/NCT01291511>

Study 5:

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

<http://ClinicalTrials.gov/show/NCT00872898>

Study 6:

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

<http://ClinicalTrials.gov/show/NCT01106430>

Study 7:

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

<http://ClinicalTrials.gov/show/NCT01081132>

Study 8:

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

<http://ClinicalTrials.gov/show/NCT01288716>

Study 9:

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

<http://ClinicalTrials.gov/show/NCT01081145>

Study 10:

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

<http://ClinicalTrials.gov/show/NCT01405053>

Study 11:

A Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride XR Tablets as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

<http://ClinicalTrials.gov/show/NCT01364662>

Study 12:

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT01174004>

Study 13:

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT00550238>

Study 14:

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

<http://ClinicalTrials.gov/show/NCT01122927>

Study 15:

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01428661>

Study 16:

A Long-Term, Open-Label, Study on Schizophrenia

<http://ClinicalTrials.gov/show/NCT01129674>

Study 17:

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT00731549>

Study 18:

Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00667810>

Study 19:

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE US)

<http://ClinicalTrials.gov/show/NCT01432444>

Study 20:

A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

<http://ClinicalTrials.gov/show/NCT01192906>

Study 21:

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

<http://ClinicalTrials.gov/show/NCT01371708>

Study 22:

Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01179516>

Study 23:

A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01072929>

Study 24:

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

<http://ClinicalTrials.gov/show/NCT01371734>

Study 25:

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01121536>

Study 26:

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00676143>

Study 27:

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

<http://ClinicalTrials.gov/show/NCT01436175>

Study 28:

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

<http://ClinicalTrials.gov/show/NCT01235585>

Study 29:

A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01114698>

Study 30:

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

<http://ClinicalTrials.gov/show/NCT01052103>

Study 31:

Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM2) (ADDRESS-98)

<http://ClinicalTrials.gov/show/NCT01349907>

Study 32:

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

<http://ClinicalTrials.gov/show/NCT01382719>

Study 33:

A Study in Schizophrenia Patients

<http://ClinicalTrials.gov/show/NCT01086748>

Study 34:

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

<http://ClinicalTrials.gov/show/NCT00723450>

Study 35:

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01435759>

Study 36:

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00998764>

Study 37:

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

<http://ClinicalTrials.gov/show/NCT01343966>

Study 38:

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01397786>

Study 39:

Vigabatrin for the Treatment of Cocaine Dependency

<http://ClinicalTrials.gov/show/NCT01281202>

Study 40:

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

<http://ClinicalTrials.gov/show/NCT00825539>

Study 41:

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01488929>

Study 42:

Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

<http://ClinicalTrials.gov/show/NCT01396447>

Study 43:

Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01412060>

Study 44:

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01467700>

Study 45:

Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01254305>

Study 46:

A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

<http://ClinicalTrials.gov/show/NCT01187407>

Study 47:

A Study in Pediatric Patients With Generalized Anxiety Disorder

<http://ClinicalTrials.gov/show/NCT01226511>

Study 48:

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

<http://ClinicalTrials.gov/show/NCT01467713>

Study 49:

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM2)

<http://ClinicalTrials.gov/show/NCT01244815>

Study 50:

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

<http://ClinicalTrials.gov/show/NCT01429116>

Study 51:

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01482221>

Study 52:

Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

<http://ClinicalTrials.gov/show/NCT01266525>

Study 53:

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

<http://ClinicalTrials.gov/show/NCT01493726>

Study 54:

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01072630>

Study 55:

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

<http://ClinicalTrials.gov/show/NCT01163032>

Study 56:

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

<http://ClinicalTrials.gov/show/NCT01175135>

Study 57:

3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01374438>

Study 58:

A Study to Evaluate the Efficacy and Safety of ALKS 9072 in Subjects With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01469039>

Study 59:

Major Depressive Disorder With Mixed Features

<http://ClinicalTrials.gov/show/NCT01423240>

Study 60:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01436149>

Study 61:

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

<http://ClinicalTrials.gov/show/NCT01193153>

Study 62:

Major Depressive Disorder With Mixed Features—Extension

<http://ClinicalTrials.gov/show/NCT01423253>

Study 63:

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01361555>

Study 64:

A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

<http://ClinicalTrials.gov/show/NCT01437657>

Study 65:

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

<http://ClinicalTrials.gov/show/NCT01234558>

Study 66:

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

<http://ClinicalTrials.gov/show/NCT01489969>

Study 67:

A Study in Prevention of Re-emergence of Depression Symptoms

<http://ClinicalTrials.gov/show/NCT01299272>

Study 68:

Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

<http://ClinicalTrials.gov/show/NCT01266174>

Study 69:

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01492374>

Study 70:

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01288079>

Study 71:

A Long-Term Study in Schizophrenia

<http://ClinicalTrials.gov/show/NCT01487083>

Study 72:

Phase 3 IGIV, 10% in Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01524887>

Study 73:

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

<http://ClinicalTrials.gov/show/NCT01328093>

Study 74:

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01369095>

Study 75:

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

<http://ClinicalTrials.gov/show/NCT01192503>

Study 76:

Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01364649>

Study 77:

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

<http://ClinicalTrials.gov/show/NCT01430754>

Study 78:

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

<http://ClinicalTrials.gov/show/NCT00868959>

Stroke

(11 clinical trials recruiting)

Study 1:

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

<http://ClinicalTrials.gov/show/NCT00856661>

Study 2:

Glyburide Advantage in Malignant Edema and Stroke Pilot (GAMES-PILOT)

<http://ClinicalTrials.gov/show/NCT01268683>

Study 3:

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

<http://ClinicalTrials.gov/show/NCT00106938>

Study 4:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

<http://ClinicalTrials.gov/show/NCT01225562>

Study 5:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 6:

Repetitive Transcranial Magnetic Stimulation (rTMS) to Contralesional Hemisphere in Patients With Stroke for Upper Limb Recovery

<http://ClinicalTrials.gov/show/NCT01049802>

Study 7:

Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

<http://ClinicalTrials.gov/show/NCT01182441>

Study 8:

Dysport® Adult Upper Limb Spasticity

<http://ClinicalTrials.gov/show/NCT01313299>

Study 9:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT00968708>

Study 10:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 11:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT013278>



Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004

www.phrma.org